Hemophilia B – Landscape & Forecast – Disease Landscape & Forecast

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in inhibitor patients). The main goal of factor IX prophylaxis and bypass agent treatment is to improve the quality of life of patients by reducing the frequency and severity of bleeding episodes. The hemophilia B therapy market will be transformed over the next 10 years owing to the entry of gene therapies and nonfactor therapies. In November 2022, the FDA approved Hemgenix (CSL Behring), the first gene therapy for hemophilia B. Fidanacogene elaparvovec (Pfizer) is the other key gene therapy in development. Upcoming novel subcutaneous nonfactor therapies will offer effective alternatives to intravenously administered factor IX products and bypass agents. These nonfactor therapies include Pfizer’s marstacimab, Novo Nordisk’s concizumab, and Sanofi’s fitusiran. Supported by insights from thought leaders, we analyze the impact of new drug therapies on the treatment of hemophilia B.

Questions answered

  • What is the current treatment landscape for hemophilia B? What are physicians’ experience and satisfaction levels with current key therapies?
  • How will hematologists differentiate between the emerging therapies?
  • What clinical roles will fitusiran, concizumab, marstacimab, and gene therapy play in the evolving hemophilia B treatment landscape?
  • How will the FIX concentrate market evolve? How will nonfactor treatment options impact the multitude of brands competing for patient share?


United States, EU5, Japan

Primary research

19 country-specific interviews with thought-leading hematologists

Supported by survey data collected for this and other Clarivate research


Diagnosed prevalence of hemophilia B +/- inhibitors by country, population segmentation by disease severity and inhibitor titer


10-year, annualized,drug-level sales and patient share of key hemophilia B therapies through 2032, segmented by brands and epidemiological subpopulations

Emerging therapies

Phase 3/PR: 5 drugs; Phase 2: 1 drug

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports